Rare but Targetable: EGFR Mutations Identified in 0.08% of Ovarian Cancers
EGFR mutations found in 0.08% of ovarian cancers; one patient achieved 17+ month response to osimertinib.
Gynecologic Oncology
Latest Posts
Age-Stratified Survival Analysis: Fertility-Preserving Hormonal Therapy vs Hysterectomy in Early-Stage Endometrial Cancer
Fertility-preserving hormonal therapy offers comparable survival to hysterectomy for women under 40 with early endometrial...
Anixa FSHR CAR-T Demonstrates Safety at 30-Fold Dose Increase in Ovarian Cancer Phase 1 Trial
Fourth cohort receiving 30x initial dose with no dose-limiting toxicities observed to date.
FDA Expands Dostarlimab Approval in Endometrial Cancer
FDA extends dostarlimab approval for all endometrial cancer patients regardless of MMR/MSI status based on...
FDA Approves Pembrolizumab Combo for Advanced or Recurrent Endometrial Cancer
FDA approves pembrolizumab + carboplatin/paclitaxel for advanced/recurrent endometrial cancer based on KEYNOTE-868 phase 3 trial...
